Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
|Articles|August 16, 2022
Daily OTC Pearl: ClearoGout
Author(s)Saro Arakelians, PharmD
ClearoGout aids in the prevention of gout attacks.
Advertisement
OTC/Lifestyle Pearl of the Day: ClearoGout
Indication: ClearoGout aids in the prevention of gout attacks.
Insight:
- Take 1-2 sachets, 4 times daily.
- Clearogout’s alkalinizing effervescent granules help relieve the painful symptoms of gout by breaking up the uric acid crystals that accumulate in the joints.
- Keep away from children.
- Store at room temperature.
Source:
Advertisement
Related to this article
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Pharmacists make a difference in patients’ lives through MTM services.
The Main Street Pharmacy Access Act would let Medicare pay pharmacists for care they can already legally provide, if pharmacies have the time.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Diuretics, eGFR, and Intensive BP Lowering in CKD: What to Watch
3
Finerenone in Heart Failure: Evidence and Practice a Year Later
4
5 Breast Cancer Advances in 2026—And The Questions They Leave Unanswered
5